US AOD Signs North American Distribution Rights Agreement for COVID-19 Self-Test Kits with AI The Nutrigene

[Asia Economy Reporter Park Ji-hwan] AI the Nutrigen's 'COVID-19 Rapid Molecular Diagnostic Kit,' which can diagnose COVID-19 infection on-site with PCR equipment-level accuracy in just 30 minutes, is entering the North American market.

On the 10th, the US global distribution group 'AOD' announced that it has signed an exclusive supply contract for the North American market with 'AI the Nutrigen' for 'NINA,' a paper-chip type high-speed, high-sensitivity molecular self-diagnostic kit that diagnoses the COVID-19 virus with 98% accuracy in 30 minutes without PCR analysis equipment.

AOD has been monitoring AI the Nutrigen's new technology NINA product since last year and, after careful observation, found that it not only achieves PCR-level accuracy but also has prepared supply pricing and production capacity to meet US market demand, leading to the signing of this contract.

AOD plans to launch the NINA project team in April and operate it at full capacity to target the North American market. They are also reviewing investment attraction plans to establish a local US production plant capable of producing over 100 million units annually through technology transfer from AI the Nutrigen.

AOD intends to apply for the US FDA Emergency Use Authorization (EUA) immediately after the clinical results from the Korean Ministry of Food and Drug Safety are released. Upon completion of the FDA EUA, they plan to hold a large-scale global showcase in the US, inviting major US university hospitals, medical companies, medical experts, and media for the 'World's First LAB ON A PAPER NINA Diagnostic Demonstration.'

'NINA' is the world's first commercially successful smart biosensor using the paper microfluidic chip (Paper-Microfluidic Chip) method. It is a cutting-edge LOP (Lab on a Paper) self-diagnostic kit that accurately diagnoses COVID-19 patients on-site with 98% sensitivity and 99% specificity within 30 minutes. Sensitivity refers to the rate of correctly identifying COVID-19 positive patients, and specificity refers to the rate of correctly identifying disease-free individuals as negative.

An AOD official stated, "NINA can confirm COVID-19 infection on-site with 98% accuracy in 30 minutes, making it a revolutionary product that can rapidly isolate and provide emergency measures for early infected patients, significantly reducing the progression to severe cases." They added, "It is expected to be a game-changer that will dramatically improve the COVID-19 prevention system in the US, where hundreds of thousands of confirmed cases occur daily."

Kim Jong-chul, CEO of AI the Nutrigen, said, "We are pleased to enter the North American market by partnering with AOD, which has various pharmaceutical industry networks including CVS in the US." He added, "We will expedite domestic clinical trials and do our best to receive clinical trial results by May at the latest."

This content was produced with the assistance of AI translation services.